These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35418462)

  • 21. Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease.
    Petersen KK; Ezzati A; Lipton RB; Gordon BA; Hassenstab J; Morris JC; Grober E
    J Prev Alzheimers Dis; 2023; 10(1):112-119. PubMed ID: 36641615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW; Desikan RS; Yokoyama JS;
    Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline.
    Lan G; Du J; Chen X; Wang Q; ; Han Y; Guo T
    Neurobiol Aging; 2023 Dec; 132():209-219. PubMed ID: 37852045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of
    Du J; Li A; Shi D; Chen X; Wang Q; Liu Z; Sun K; Guo T;
    Neurology; 2023 Jul; 101(1):e40-e49. PubMed ID: 37188537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau.
    Butt OH; Meeker KL; Wisch JK; Schindler SE; Fagan AM; Benzinger TLS; Cruchaga C; Holtzman DM; Morris JC; Ances BM
    Alzheimers Dement; 2022 Jan; 18(1):116-126. PubMed ID: 34002449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.
    Cooper JG; Ghodsi M; Stukas S; Leach S; Brooks-Wilson A; Wellington CL
    Alzheimers Dement; 2024 Jun; 20(6):4373-4380. PubMed ID: 38752508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
    Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
    Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in Daily Physical Activity by Alzheimer's Risk Markers Among Older Adults.
    Marino FR; Deal JA; Dougherty RJ; Bilgel M; Tian Q; An Y; Simonsick EM; Resnick SM; Ferrucci L; Spira AP; Wanigatunga AA; Schrack JA
    J Gerontol A Biol Sci Med Sci; 2024 Jul; 79(7):. PubMed ID: 38742659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer's disease in healthy samples across the lifespan.
    Wang Y; Grydeland H; Roe JM; Pan M; Magnussen F; Amlien IK; Watne LO; Idland AV; Bertram L; Gundersen TE; Pascual-Leone A; Cabello-Toscano M; Tormos JM; Bartres-Faz D; Drevon CA; Fjell AM; Walhovd KW
    Brain Behav Immun; 2022 Feb; 100():243-253. PubMed ID: 34920091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
    Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
    Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults.
    Malek-Ahmadi M; Su Y; Ghisays V; Luo J; Devadas V; Chen Y; Lee W; Protas H; Chen K; Zetterberg H; Blennow K; Caselli RJ; Reiman EM
    Alzheimers Res Ther; 2023 Apr; 15(1):74. PubMed ID: 37038190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
    Nemes S; Logan PE; Manchella MK; Mundada NS; La Joie R; Polsinelli AJ; Hammers DB; Koeppe RA; Foroud TM; Nudelman KN; Eloyan A; Iaccarino L; Dorsant-Ardón V; Taurone A; Thangarajah M; Dage JL; Aisen P; Grinberg LT; Jack CR; Kramer J; Kukull WA; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Vemuri P; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Womack KB; Wolk DA; Rabinovici GD; Carrillo MC; Dickerson BC; Apostolova LG;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S49-S63. PubMed ID: 37496307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
    Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic functional connectivity alterations in cognitively intact elderly APOE ε4 carriers measured by eigenvector centrality mapping are related to cognition and CSF biomarkers: a preliminary study.
    Luo X; Qiu T; Jia Y; Huang P; Xu X; Yu X; Shen Z; Jiaerken Y; Guan X; Zhou J; Zhang M;
    Brain Imaging Behav; 2017 Oct; 11(5):1290-1301. PubMed ID: 27714554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.